What are the cutaneous side effects of infliximab?
Best insight from top research papers
Cutaneous side effects of infliximab include psoriasis-like eruptions, eczema, cutaneous infections, alopecia areata, atopic dermatitis, urticaria, and drug-induced vasculitis .
Answers from top 5 papers
More filters
| Papers (5) | Insight |
|---|---|
| The provided paper is about the cutaneous side effects of dupilumab, not infliximab. The paper does not provide information about the cutaneous side effects of infliximab. | |
| The paper mentions that the cutaneous side effects of infliximab include psoriasis-like eruptions, eczema, cutaneous infections, and injection site reactions. | |
2 Citations | The paper mentions a rare dermatological side effect of infliximab, which is an acneiform reaction. |
| The paper does not specifically mention the cutaneous side effects of infliximab. The paper discusses a rare case of infliximab-induced myeloperoxidase-cytoplasmic antineutrophil cytoplasmic autoantibody positive cutaneous vasculitis. | |
1 Citations | The paper does not specifically mention the cutaneous side effects of infliximab. |
Related Questions
How does the FDA's warning on adalimumab affected?5 answersThe FDA's warnings on adalimumab have highlighted various aspects of its safety and efficacy. Adalimumab, a TNF-α blocking agent, is associated with common side effects like injection site reactions and infections. Studies have shown that adalimumab may increase the risk of malignancies, including lymphoma and non-melanoma skin cancer, compared to control groups. Despite these concerns, adalimumab remains a valuable treatment option for various autoimmune conditions, with ongoing benefits demonstrated in long-term extension studies and patient registries. The FDA's scrutiny emphasizes the need for monitoring and balancing the drug's advantages against potential risks, especially in patients with comorbidities like hepatic or renal conditions. Overall, the FDA's warnings underscore the importance of careful consideration and monitoring when using adalimumab for inflammatory conditions.
What are the adverse effects of topical ruxolitinib?5 answersTopical ruxolitinib has been found to have a favorable safety profile with low rates of mild-to-moderate treatment-related adverse events. The most common adverse effects reported include application site acne, application site itching, common cold, headache, urinary tract infection, application site redness, and fever.
What is the effect of infliximab on IBD in mice?3 answersInfliximab does not directly bind to mouse TNF-α and does not inhibit TNF-α-induced NF-κB stimulation in mouse fibroblasts. In a TNF-α-independent infection model of chronic colitis in mice, Infliximab had no effect on clinical outcome or macrophage cell phenotype or number. However, it did enhance apoptosis of colonic immune cells significantly. Infliximab is a human-mouse chimeric antibody to tumor necrosis factor used for patients with inflammatory bowel disease (IBD). Development of antibodies to infliximab in some patients has been associated with loss of clinical response and lower serum infliximab levels. Tumor necrosis factor (TNF) inhibitors, including infliximab, have led to a change in the management of inflammatory bowel disease (IBD). In a study using mouse models of steatotic or cholestatic liver injury, Infliximab was found to modulate the adaptive remodeling of the biliary architecture and limit extracellular matrix deposition.
What are the side effects of biologic agents for treating atopic dermatitis?5 answersBiologic agents used for treating atopic dermatitis can have various side effects. Monoclonal antibodies targeting the Th1 and Th17 pathways have been associated with significant side effects, including impairment in immune responses to pathogens. Some of the reported side effects of biologic agents include AD acceleration and paradoxical adverse events (PAEs). Chronic systemic corticosteroid use, which is an alternative to biologic therapy, is associated with significant side effects as well. However, biologics targeting Th2-mediated inflammation have had fewer reported side effects. It is important to note that the safety profiles of new biologics are still being studied, and long-term safety monitoring is required.
What are the side effects of JAK inhibitors in dermatology?5 answersJAK inhibitors have been shown to have efficacy in treating various dermatologic conditions, but they can also have side effects. The common side effects of oral JAK inhibitors include upper respiratory infections, nasopharyngitis, nausea, headache, and acne. Serious adverse events reported with JAK inhibitors include venous thromboembolism, cardiovascular events, and serious infections. Regular monitoring of blood parameters, liver and renal function, viral markers, and ruling out tuberculosis is recommended before starting JAK inhibitor therapy. It is important for dermatologists to consider patients' baseline risk factors for developing serious complications when prescribing oral JAK inhibitors. Acne is a common adverse effect of JAK inhibitors, with mild-to-moderate acne being reported in clinical trials. Topical therapy has been successful in treating acne associated with JAK inhibitor use, and systemic therapy should be reserved for severe cases.
What are the most common side effects of celecoxib?4 answersThe most common side effects of celecoxib include severe cardiovascular complications, gastrointestinal adverse effects such as esophagitis, and potential impact on renal function in cirrhotic patients with ascites. Celecoxib is also associated with symptomatic gastrointestinal ulcers and their complications.